Drug Facts
Composition & Profile
Identifiers & Packaging
16 HOW SUPPLIED/STORAGE AND HANDLING Tranexamic Acid in Sodium Chloride Injection is supplied as a sterile, unpreserved, colorless solution in a single-dose polymeric bag containing 1000 mg tranexamic acid in 100 mL of solution (10 mg/mL) sealed with a Twist Off port and oversealed in an aluminum pouch as follows: Strength Package NDC Number 1000 mg (10 mg/mL) 1 single-dose bag 14789-115-08 10 bags per carton 14789-115-05 Discard any unused portion. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].; Principal Display Panel – 100 mL Bag Label TO OPEN-TEAR AT NOTCH LEAVE BAG IN FOIL OVERWRAP UNTIL USE 100 mL Single-Dose Container Discard Unused Portion NDC 14789-115-08 Tranexamic Acid in 0.7% Sodium Chloride Injection 1,000 mg per 100 mL (10 mg per mL) For Intravenous Infusion Only. Each mL contains 10 mg of Tranexamic Acid, USP 7 mg of Sodium Chloride, USP in Water for Injection, USP. pH 6.5 – 8.0. DOSAGE: See prescribing information for complete information on dosing and administration. CAUTIONS: Check for minute leaks by squeezing bag firmly. Do not use unless solution is clear. Do not add supplemental medication. Must not be used in series connections. STORAGE: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [see USP Controlled Room Temperature] Rx Only Sterile, Unpreserved, Nonpyrogenic NEXUS PHARMACEUTICALS Manufactured for: Nexus Pharmaceuticals, Inc. Lincolnshire, IL 60069 TRA10-100LBL-FR001 Principal Display Panel – 100 mL Bag Label; Principal Display Panel – Carton Label NDC 14789-115-05 Rx Only Tranexamic Acid in 0.7% Sodium Chloride Injection 1,000 mg per 100 mL (10 mg per mL) 10 x 100 mL Single-Dose Containers For Intravenous Infusion Only. NEXUS PHARMACEUTICALS TRACT01GBR03 Principal Display Panel – Carton Label
- 16 HOW SUPPLIED/STORAGE AND HANDLING Tranexamic Acid in Sodium Chloride Injection is supplied as a sterile, unpreserved, colorless solution in a single-dose polymeric bag containing 1000 mg tranexamic acid in 100 mL of solution (10 mg/mL) sealed with a Twist Off port and oversealed in an aluminum pouch as follows: Strength Package NDC Number 1000 mg (10 mg/mL) 1 single-dose bag 14789-115-08 10 bags per carton 14789-115-05 Discard any unused portion. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
- Principal Display Panel – 100 mL Bag Label TO OPEN-TEAR AT NOTCH LEAVE BAG IN FOIL OVERWRAP UNTIL USE 100 mL Single-Dose Container Discard Unused Portion NDC 14789-115-08 Tranexamic Acid in 0.7% Sodium Chloride Injection 1,000 mg per 100 mL (10 mg per mL) For Intravenous Infusion Only. Each mL contains 10 mg of Tranexamic Acid, USP 7 mg of Sodium Chloride, USP in Water for Injection, USP. pH 6.5 – 8.0. DOSAGE: See prescribing information for complete information on dosing and administration. CAUTIONS: Check for minute leaks by squeezing bag firmly. Do not use unless solution is clear. Do not add supplemental medication. Must not be used in series connections. STORAGE: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [see USP Controlled Room Temperature] Rx Only Sterile, Unpreserved, Nonpyrogenic NEXUS PHARMACEUTICALS Manufactured for: Nexus Pharmaceuticals, Inc. Lincolnshire, IL 60069 TRA10-100LBL-FR001 Principal Display Panel – 100 mL Bag Label
- Principal Display Panel – Carton Label NDC 14789-115-05 Rx Only Tranexamic Acid in 0.7% Sodium Chloride Injection 1,000 mg per 100 mL (10 mg per mL) 10 x 100 mL Single-Dose Containers For Intravenous Infusion Only. NEXUS PHARMACEUTICALS TRACT01GBR03 Principal Display Panel – Carton Label
Overview
Tranexamic acid is trans-4-(aminomethyl)cyclohexanecarboxylic acid, an antifibrinolytic agent. Tranexamic acid is a white crystalline powder. The structural formula is Empirical Formula: C 8 H 15 NO 2 Molecular Weight: 157.2 Tranexamic Acid in Sodium Chloride Injection is a clear to colorless sterile, nonpyrogenic injectable solution for intravenous administration. Each IV bag contains 1,000 mg tranexamic acid, USP, 700 mg of sodium chloride, USP and Water for Injection, USP. The aqueous solution has a pH of 6.5 to 8.0. Structural Formula
Indications & Usage
Tranexamic Acid in Sodium Chloride Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. Tranexamic Acid in Sodium Chloride Injection is an antifibrinolytic indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction ( 1 ).
Dosage & Administration
Before Extraction: Administer 10 mg/kg actual body weight of Tranexamic Acid in Sodium Chloride Injection intravenously with replacement therapy. After Extraction: Administer 10 mg/kg actual body weight 3 to 4 times daily for 2 to 8 days. Infuse no more than 10 mL/minute to avoid hypotension ( 2.1 ). Reduce the dosage for patients with renal impairment ( 2.2 , 8.6 ). 2.1 Recommended Dosage The recommended dose of Tranexamic Acid in Sodium Chloride Injection is 10 mg/kg actual body weight intravenously administered as a single dose, immediately before tooth extractions. Infuse no more than 10 mL/minute to avoid hypotension [see Warnings and Precautions ( 5.1 )] . Following tooth extraction, Tranexamic Acid in Sodium Chloride Injection may be administered for 2 to 8 days at a dose of 10 mg/kg actual body weight three to four times daily, intravenously. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use Tranexamic Acid in Sodium Chloride Injection if particulate matter or coloration is seen. Tranexamic Acid in Sodium Chloride Injection should NOT be mixed with blood. The drug is a synthetic amino acid and should NOT be mixed with solutions containing penicillin. The premix flexible plastic container bag contains no preservative; discard any unused portion. 2.2 Recommended Dosage for Patients with Varying Degrees of Renal Impairment* For patients with moderate to severe impaired renal function, the following dosages are recommended: Table 1. Recommended Dosage in Patients with Varying Degrees of Renal Impairment *Dose reduction is recommended for all doses, both before and after tooth extraction. Serum Creatinine (mg/dL) Tranexamic Acid in Sodium Chloride Injection Intravenous Dosage 1.36 to 2.83 (120 to 250 micromol/L) 10 mg/kg twice daily 2.83 to 5.66 (250 to 500 micromol/L) 10 mg/kg daily >5.66 (>500 micromol/L) 10 mg/kg every 48 hours or 5 mg/kg every 24 hours
Warnings & Precautions
Risk of Thrombosis with concomitant use of Factor IX: Avoid concomitant use ( 5.1 ). Seizures: Inadvertent injection into neuraxial system may result in seizures ( 5.2 ). Hypersensitivity Reactions: In case of severe reaction, discontinue use and seek immediate medical attention ( 5.3 ). Visual Disturbances: Visual or ocular adverse effects may occur. Discontinue use if visual or ocular symptoms occur ( 5.4 ). Dizziness. Advise patients not to drive if dizziness occurs ( 5.5 ). 5.1 Thromboembolic Risk Tranexamic Acid in Sodium Chloride Injection is contraindicated in patients with active intravascular clotting. Tranexamic acid is an antifibrinolytic and may increase the risk of thromboembolic events. Venous and arterial thrombosis or thromboembolism has been reported in patients treated with tranexamic acid. Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection and medical products that are pro-thrombotic, as the risk of thrombosis may be increased. These medications include but are not limited to, Factor IX Complex concentrates, Anti-inhibitor Coagulant concentrates, and hormonal contraceptives [see Drug Interactions ( 7.1 ), Use in Specific Populations ( 8.3 )] . 5.2 Seizures Tranexamic acid may cause seizures, including focal and generalized seizures. The most common setting for tranexamic acid-induced seizures has been during cardiovascular surgery (a setting in which Tranexamic Acid in Sodium Chloride Injection is not FDA approved and which uses doses of up to ten-fold higher than the recommended human dose and in patients inadvertently given tranexamic acid into the neuraxial system). Tranexamic Acid in Sodium Chloride Injection is not approved and not recommended for neuraxial administration. Consider dose reduction during surgery and dose adjustments for patients with clinical conditions such as renal dysfunction. Closely monitor the patient during surgery. Consider electroencephalogram (EEG) monitoring for patients with history of seizures or who experience myoclonic movements, twitching, or show evidence of focal seizures. Discontinue Tranexamic Acid in Sodium Chloride Injection if seizures occur. 5.3 Hypersensitivity Reactions Cases of hypersensitivity reactions, including anaphylactic reactions, have occurred with use of intravenous tranexamic acid. Discontinue treatment with Tranexamic Acid in Sodium Chloride Injection if serious reaction occurs, provide appropriate medical management, and do not restart treatment. Tranexamic Acid in Sodium Chloride Injection is contraindicated in patients with a history of hypersensitivity to tranexamic acid. 5.4 Visual Disturbances Although not seen in humans, focal areas of retinal degeneration have been observed in cats and dogs following oral or intravenous tranexamic acid at doses between 250 to 1600 mg/kg/day (1.6 to 22 times the recommended usual human dose based on body surface area) from 6 days to 1 year. No retinal changes have been observed in eye examinations of patients treated with tranexamic acid for up to 8 years. Patients expected to be treated for greater than 3 months may consider ophthalmic monitoring including visual acuity and optical coherence tomography at regular intervals. Discontinue Tranexamic Acid in Sodium Chloride Injection if changes in ophthalmological examination occurs. 5.5 Dizziness Tranexamic acid may cause dizziness. Concomitant use of other drugs that may also cause dizziness may worsen this effect. Advise patients to avoid driving or using machines until they know how Tranexamic Acid in Sodium Chloride Injection affects them.
Contraindications
Tranexamic Acid in Sodium Chloride Injection is contraindicated: In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid in such patients. In patients with active intravascular clotting [see Warnings and Precautions ( 5.1 )] . In patients with hypersensitivity to tranexamic acid or any of the ingredients [see Warnings and Precautions ( 5.3 )] . In patients with subarachnoid hemorrhage, due to risk of cerebral edema and cerebral infarction ( 4 ). In patients with active intravascular clotting ( 4 ). In patients with severe hypersensitivity reactions to tranexamic acid or any of the ingredients ( 4 ).
Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: Thromboembolic Risk [see Warnings and Precautions ( 5.1 )] Seizures [see Warnings and Precautions ( 5.2 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.3 )] Visual Disturbances [see Warnings and Precautions ( 5.4 )] Dizziness [see Warnings and Precautions ( 5.5 )] Most common adverse reactions are nausea, vomiting, diarrhea, allergic dermatitis, giddiness, hypotension, and thromboembolic events ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Nexus Pharmaceuticals at (855) 642-2594 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of tranexamic acid. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal disturbances (nausea, vomiting, diarrhea) may occur and may resolve with dose-reduction. Allergic dermatitis and giddiness have been reported. Hypotension has been reported when intravenous injection is too rapid. Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, and central retinal artery, vein obstruction and cases associated with concomitant use of combination hormonal contraceptives) have been rarely reported in patients receiving tranexamic acid for indications other than hemorrhage prevention in patients with hemophilia. Convulsion, cromatopsia, and visual impairment have also been reported. Anaphylaxis or anaphylactoid reactions have been reported that are suggestive of a causal relationship.
Drug Interactions
Prothrombotic Medical Products: Avoid concomitant use, can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid ( 5.1 , 7.1 , 8.3 ). 7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.3 )].
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.